Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$104.06 USD

104.06
4,516,085

-0.77 (-0.74%)

Updated Aug 6, 2025 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View

by Zacks Equity Research

Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.

    Zacks Equity Research

    Boston Scientific (BSX) Beats on Earnings & Revenues in Q4

    by Zacks Equity Research

    Boston Scientific (BSX) has posted positive results with both its top line and bottom line beating the Zacks Consensus Estimate.

      Tracey Ryniec headshot

      5 Stocks with Spectacular Earnings Charts

      by Tracey Ryniec

      These 5 companies have perfect earnings beat records for the last 5 years.

        Zacks Equity Research

        Medical Product Earnings Due on Feb 2: BDX, BSX, IDXX, ATHN

        by Zacks Equity Research

        The medical sector is likely to see 2.9% earnings growth on 5.7% higher revenues in the quarter.

          Zacks Equity Research

          Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?

          by Zacks Equity Research

          Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.

            Zacks Equity Research

            Boston Scientific Down on Risks; Innovations Raise Hope

            by Zacks Equity Research

            On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

              Zacks Equity Research

              Boston Scientific Acquires Neovasc to Boost Heart Business

              by Zacks Equity Research

              Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.

                Zacks Equity Research

                Boston Scientific (BSX) Inks $75 Million Deal with Neovasc

                by Zacks Equity Research

                Boston Scientific Corporation (BSX) recently inked a deal with specialty medical device company Neovasc Inc.